Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled trial of HS-10383 in refractory or unexplained chronic cough (RUCC) in Chinese adults
CTR20240165Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10383 in refractory chronic cough (RCC), sponsored by Hengrui Therapeutics. Started Jan 2024; status: completed.
02
Drugs
HS-10383
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on CTR20240165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240165.